ArticleDiscover oncology2025
Advances in genomic and pharmacokinetic profiling for clinical stratification of metastatic breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic breast cancer (MBC) is the most significant clinical challenge in patient care; hence, we need new personalized therapeutic targets and innovative inhibitors. Genomic, proteomic, and structural analysis can be a pivotal tool for faster and more cost-efficient lead discovery.
methodsThe study employed gene expression profiling (Microarray, PCR, Bulk RNA-Seq) and computer-aided drug design, including structural modeling, virtual screening, docking, pharmacophore modeling, ADMET analysis, and NMA dynamics. A large compound library was screened to identify stable, high-affinity protein-ligand interactions targeting key proteins in metastatic breast cancer.
resultsAcross primary breast tumors and metastatic organs (lung, liver, bone, and brain), we identified significantly altered genes after filtering a large set of redundant DEG entries. Scored Network analysis showed 8 gene modules linked to metastasis, validated through pathway databases. Key genes including AR, AKT1, UBC, CDH1, SMAD3, ROR1, and ROR2 were associated with chemotherapy resistance and poor prognosis. Structural and drug interaction studies identified therapeutically targetable genes, with candidate compounds showing promising pharmacokinetics and safety. These findings offer insights into metastatic breast cancer and potential paths for improved diagnosis and treatment.
conclusionThe computational results reveal that kinases like AKT1, ROR1, and ROR2, and non-kinase targets like UBC, RPS6, CDH1, AR, and SMAD3, are the most promising candidates. All screened compounds showed varying strong interacting profiles, with Ellagic Acid and Erioflorin standing out as potent candidates against critical targets in metastatic breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.